Compare AdaptHealth Corp (AHCO) vs Ares Capital Corporation (ARCC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AdaptHealth Corp vs Ares Capital Corporation — how do they compare? AdaptHealth Corp trades at $5.62 (market cap $753.09M), while Ares Capital Corporation trades at $19.78 (market cap $14.34B). The key difference: Ares Capital Corporation is far larger — about 19× AdaptHealth Corp's market cap, and Ares Capital Corporation pays a 9.61% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | ARCC | |
|---|---|---|
Market Cap | $753.09M | $14.34B |
Sector | Health | Financials |
52-Week High | $13.38 | $22.68 |
52-Week Low | $5.22 | $17.45 |
Enterprise Value | $2.77B | — |
Dividend Yield | — | 9.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $5.63, up 7.85% today but remains under significant pressure after recent earnings disappointments. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal negative profitability with a -6.82% net margin and three consecutive quarterly earnings misses. The company is restructuring by selling its diabetes unit to focus on sleep and respiratory care, but faces multiple securities fraud investigations following guidance revisions.
Despite 75% analyst buy ratings and an $11 consensus price target suggesting 95% upside, substantial risks exist including ongoing legal probes, execution challenges with new fixed-price contracts, and negative cash flow trends. The stock presents high-risk speculation amid operational restructuring and legal uncertainties.
ARCC trades at $19.98, down 0.15% on the day, with a P/E of 14.9 and P/B of 1.03. Recent quarterly earnings have consistently missed expectations, with Q2 2026 EPS of $0.47 falling short of the $0.4731 estimate. Technical indicators show a bullish moving average signal but bearish oscillators, with RSI at 78.37 suggesting overbought conditions. The company maintains a strong dividend yield of approximately 9.6% with consistent $0.48 quarterly payments.
While ARCC offers attractive income with its high dividend yield and strong analyst support (24 buy ratings), investors face risks from declining revenue trends and compressed earnings. The stock trades near consensus price targets, limiting near-term upside potential. Credit quality concerns in the private lending sector and potential interest rate sensitivity present additional headwinds for this business development company.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AdaptHealth Corp
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →
